908 Devices Inc Dossier
|
SectorInformation Technology IndustryElectronic Equipment, Instruments & Components Beta (adjusted)0.78 Intrinsic Value $7.83median of 3 methodsbased on filings through 30 Jun 2026 Market Price $12.34Price as of 30 Sep 2026 OvervaluedIntrinsic value is 37% below the market price −50% · IV below pricenear fair value ±15%IV above price · +50% Data confidence Sign in to view data confidence Market Cap $510.1M Enterprise Value $447M Shares Outstanding 37.5M diluted Moat Rating None Next Earnings Date10 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary 908 Devices Inc. (MASS) is successfully executing a strategic pivot toward high-growth, frontline chemical and narcotics detection. Following the divestiture of its desktop bioprocessing business in early 2025, the company has streamlined its cost structure and focused on its core handheld mass spectrometry and optical spectroscopy platforms. The recent acquisition of NIRLAB AG in May 2026 significantly expands its narcotics detection portfolio, introduces a high-retention SaaS recurring revenue model, and accelerates international expansion. Backed by a robust debt-free balance sheet with over $111 million in cash, 908 Devices is well-positioned to capture growing global defense and public safety budgets. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$10.00 Mean target$11.00 High · most bullish analyst$12.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $8.0015% Integration delays with NIRLAB or a slowdown in state and local government procurement cycles lead to revenue missing the lower end of guidance. Continued high R&D and SG&A spending, combined with slower adoption of new handheld platforms, prolongs unprofitable operations and accelerates cash burn, depressing the stock price. Base CaseCentral scenario $11.0055% Matches the consensus mean908 Devices achieves its raised FY 2026 revenue guidance of $67.0 million to $70.0 million, representing 19% to 25% year-over-year growth. Handheld product and service revenues grow steadily, supported by the integration of NIRLAB and continued state and local public safety demand. Adjusted gross margins remain stable in the mid-to-high-50% range, and Adjusted EBITDA losses narrow significantly. Bull CaseUpside scenario $12.0030% Rapid adoption of the next-generation MX908 platform and accelerated SaaS recurring revenue from the NIRLAB integration drive revenue growth above the high end of guidance. Stronger-than-expected federal defense contracts and state/local public safety orders lead to operating leverage, pushing the company toward positive Adjusted EBITDA and cash flow generation ahead of schedule. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |